Yochi Slonim, Anima Biotech CEO

Ab­b­Vie signs mR­NA pact with An­i­ma Biotech for $42M up­front

Ab­b­Vie is part­ner­ing on mR­NA, hop­ing to de­vel­op new med­i­cines with the help of a small biotech’s tech­nol­o­gy plat­form, the com­pa­ny an­nounced to­day.

An­i­ma Biotech will re­ceive an up­front pay­ment of $42 mil­lion from Ab­b­Vie. An­oth­er $540 mil­lion is on the line in the form of op­tion fees and re­search and de­vel­op­ment mile­stones for the dis­cov­ery and de­vel­op­ment of mR­NA bi­ol­o­gy mod­u­la­tors across three tar­gets in on­col­o­gy and im­munol­o­gy us­ing the com­pa­ny’s Light­ning plat­form. Com­mer­cial mile­stones and tiered roy­al­ties could al­so lead to more pay­outs for An­i­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.